Kahlem Pascal, Dörken Bernd, Schmitt Clemens A
Department of Hematology, Oncology, and Tumor Immunology, Humboldt University, Charité, Berlin, Germany.
J Clin Invest. 2004 Jan;113(2):169-74. doi: 10.1172/JCI20784.
Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.
DNA作为抗癌治疗的主要靶点，其损伤会引发细胞程序性反应。除细胞凋亡外，治疗介导的早衰已被确认为另一种影响癌症治疗结果的药物反应程序。在此，我们讨论诱导衰老究竟是治疗干预的有益还是有害后果。
